Profits rise for SmithKline
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Profits rise for SmithKline
SmithKline Beecham, chaired by Sir Peter Walters (below), announced a 9 per cent increase in third quarter pre-tax profits to pounds 310m bringing the nine- month total to pounds 1.48bn, a 59 per cent increase. Sales from continuing operations rose 16 per cent as new products continued to make up for declining turnover from ulcer treatment Tagamet. Jan Leschly, chief executive, said the quarter's biggest achievement was the launch of an over-the-counter version of Tagamet to treat heartburn. SB's A shares closed 9p higher at 673p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
0Comments